RU486 (Mifepristone) was purchased from OChem. BODIPY® 493/503, SE (4, 3, 5, succinimidyl ester) and 5-TAMRA, SE (5-carboxytetramethylrhodamine, succinimidyl ester) were purchased from Invitrogen. 17-AAG (17-(Allylamino)-17-demethoxygeldanamycin), vorinostat, panobinostat and FK506 were purchased from LC laboratories. VER-155008 was purchased from Santa Cruz Biotechnology. Femto ELISA-AP substrate was purchased from G Biosciences. All other chemicals were purchased from Sigma-Aldrich and used as received unless otherwise noted.
Scheme S1. Synthetic scheme for the synthesis of RU486-BODIPY and RU486-TAMRA.
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Compound 1: Compound 1 was synthesized according to published procedure. 1 Compound 2: Compound 2 was synthesized from compound 1 according to published procedure. 2 Compound 3: Compound 2 (20 mg, 38 µmol, 1 eq) was dissolved in 1 mL dry DMF under argon atmosphere and Et 3 N (5.5 µL, 40 µmol, 1.05 eq) and HATU (15 mg, 40 µmol, 1.05 eq) were added. The solution was stirred for 1 minute, then N-Boc-2,2'-(ethylenedioxy)diethylamine (10 µL, 41 µmol, 1.1 eq) and Et 3 N (5.8 µL, 41 µmol, 1.1 eq) were added, and the reaction mixture was stirred for 45 minutes. 
RU486-BODIPY:
Compound 3 (10 mg, 13 µmol, 1 eq) was dissolved in 0.5 mL DCM:TFA (9:1) and stirred for 30 minutes at room temperature (NOTICE: prolonged reaction time leads to dehydration at 17α). The solvents were removed under reduced pressure, the residue was triturated with Et 2 O and dried again under reduced pressure. The crude product was used without further purification. Thus, the residue was dissolved in 750 µL dry DMF under argon atmosphere and Et 3 N (7.3 µL, 52 µmol, 4 eq) and BODIPY® 493/503 SE (6 mg, 14.3 µmol, 1.1 eq) were added. The reaction was stirred at room temperature for 2 hours then solvent was removed under reduced pressure. The crude residue was dissolved in 2 mL DMSO:ACN:water 2:1:1 and purified on preparative HPLC (gradient 20 to 80% ACN in 20 minutes, for more details see
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Preparative HPLC conditions below). Retention time: 15.68 minutes. After removal of solvents, 5.3 mg (5.5 µmol, yield 42%) of RU486-BODIPY as an orange solid were obtained. 1 
RU486-TAMRA:
Prepared similarly to RU486-BODIPY from 5-TAMRA SE (7.5 mg, 14.3 µmol, 1.1 eq). The crude product was purified on preparative HPLC (gradient 10 to 100% ACN in 20 minutes, for more details see Preparative HPLC conditions below). Retention time: 14.93 minutes. After removal of solvents, 6.7 mg (6.2 µmol, yield 48%) of RU486-TAMRA as a purple solid were obtained. 
S6
Preparative HPLC conditions. Preparative separations were performed on Agilent HPLC system (1200 series) with Luna 10 µm PREP C18(2) column (250.0 X 21.2 mm, 100 Å), using a water-acetonitrile solvent system (solvent A = water, solvent B = acetonitrile, both with 0.05% TFA as an additive) at flow rate of 15 mL/min.
Molecular modeling
The 3D structure of human PR co-crystalized with RU486 [PDB: 2W8Y] was used as a template.
RU486-BODIPY was inserted into the protein and its steroidal skeleton was superimposed on RU486 using Biopolymer mode in Insight II. RU486 was then extracted from the complex. The RU486-BODIPY-PR complex was refined using Discover 3 in Insight II. For this energy minimization step, Discover 3 was run for 10,000 iterations, using CVFF force field and a distance dependent dielectric constant of 2 to approximate for water in the protein. Images were rendered using UCSF Chimera 1.5.3.
LogP measurement and calculation
LogP was measured using the shake flask method. Approximately 0.5 mg of the tested compound was dissolved in 1 mL of a 1:1 mixture of water/1-octanol in a glass vial. The solution was vortexed for ~1 minute until completely dissolved and then placed on a rotator for gentle mixing over 6 h. The vial was then removed and allowed to sit for 16 h. A sample was removed from each layer and the concentration of the tested compound was determined by comparing the sample's fluorescence intensity against a calibration curve (calibration curve was prepared for water and 1-octanol separately). The logP was calculated using the following equation: logP = log 10 (C octanol /C water ), where C octanol is the concentration in the 1-octanol layer, and C water is the concentration in the water layer.
Cell cultures methods
T47-D and MDA-MB-231 cells were purchased from ATCC (HTB-133 and HTB-26, respectively). MDA-MB-231 cells were maintained in DMEM medium (Cellgro) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals) and T47-D cells were maintained in RPMI 1640 medium (Cellgro) supplemented with 10% FBS and human insulin (0.2 unit/mL, Sigma). Both cell lines were cultured in a humidified atmosphere containing 5% CO 2 at 37 °C. Three days before experiments, cells were seeded in 8-well borosilicate cover-glass chambers (Nunc* Lab-Tek* Chambered Coverglass, Thermo Scientific) or in 48-well plates (Corning* Costar* cell culture plates) with their respective maintenance medium (above). 24-36 hours prior to experiments, maintenance medium was removed and cells were washed twice with HBSS.
Then, for MDA-MB-231, DMEM medium (without phenol red) supplemented with 5% dextran charcoal stripped (CDS) FBS was added and for T47D, RPMI 1640 medium (without phenol red) supplemented with 5% CDS FBS and human insulin (0.2 unit/mL) was added.
Stock solutions of all reported and used molecules (1 or 10 mM) were prepared in DMSO and stored at −20 °C. Before use, stocks were diluted with either DMEM or RPMI 1640 (both without phenol red, supplemented with 5% CDS FBS) to the final working concentration (final DMSO content was always > 0.1% v/v).
Alkaline phosphatase assay
Alkaline phosphatase was assayed using the multiwall format described by Markiewicz and Gurpide. 3 T47D cells were plated in 48-well dishes, and 24 hours before the start of the experiment, media was changed to the phenol red-free formulation with reduced and charcoal- 
Fluorescence imaging
Unless otherwise stated, cells were incubated with either RU486-BODIPY or RU486-TAMRA for 10 minutes in their respective medium (see cell cultures) then Hoechst stain (10 µg/mL) was added and incubation was resumed for additional 5 minutes. The incubation medium was then removed, cells were washed twice with HBSS and fresh medium (without phenol red,
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supplemented with 5% CDS FBS and insulin) was introduced. Cells were kept in a humidified atmosphere containing 5% CO 2 at 37 °C until imaged. Cells were imaged on a Zeiss Axiovert 200M microscope with a 40x (oil immersion 1.3 NA) objective and cooled EMCCD camera (Cascade II:1024, Photometrics) controlled by METAFLUOR 6.1 software (Universal Imaging).
Imaging experiments of RU486-BODIPY were performed with excitation at 495 nm (10 nm bandwidth), emission at 535 nm (45 nm bandwidth), and dichroic mirror at 515 nm. Imaging experiments of RU486-TAMRA were performed with excitation at 540 nm (25 nm bandwidth), emission at 595 nm (50 nm bandwidth), and dichroic mirror at 560 nm. Images were processed with ImageJ (image processing and analysis software; National Institutes of Health). Contrast and brightness were adjusted manually (ImageJ) with no background subtraction. Images were similarly scaled unless otherwise noted.
Antibody staining
T47D or MDA-MB-231 cells were cultured and treated with RU486-BODIPY and Hoechst dye as described in the Fluorescence Imaging method above. After washing off the dyes, cells were incubated in a humidified atmosphere containing 5% CO 2 at 37 °C for 1 hour. Cells were then washed twice with HBSS and fixed with IHC Zinc Fixative (BD Pharmingen, #550523) for 30 minutes. The fixed cells were washed twice with PBS containing 1 % BSA and incubated in this medium for 15 minutes. Cells were then washed again with HBSS (twice) and incubated with polyclonal rabbit anti-human progesterone receptor primary antibody (Dako, #A0098), at 1:500 dilution in PBS containing 1 % BSA, for 18 hours at room temperature. Cells were then washed three times (x 5 minutes) with PBS 1 % BSA and incubated with AlexaFluor®594 goat antirabbit IgG (Life Technologies #A11037), at 1:500 dilution in PBS 1 % BSA, for 3 hours at room temperature. Cells were then washed three times (x 5 minutes) with PBS 1 % BSA and kept in this medium for imaging. Imaging was performed as described in the Fluorescence Imaging method above with the addition of excitation at 580 nm (20 nm bandwidth), emission at 653 nm (95 nm bandwidth) and dichroic mirror at 600 nm for AlexFluor®594 detection.
Inhibition of PR complex components
T47D cells were incubated with 10 µM Vorinostat, Panobinostat, VER155008 or methylene blue for 12 hours, 10 µM FK506 for 2 hours, 500 µM EHNA for 1 hour or 0.1 % v/v DMSO for 12 S9 hours as control, before treatment with 5 nM RU486-BODIPY for 15 minutes. Cell were then washed twice with HBSS containing the respective inhibitor at similar concentration and incubated with fresh media containing the respective inhibitor at similar concentration for an additional 45 minutes. Cells were then imaged and the ratio of nuclear vs. cytoplasmic fluorescence was determined by drawing regions of interest for each cellular compartment of a specific cell and quantifying the mean fluorescence intensity (using ImageJ). This was repeated for 30 cells in each experimental setting.
In vivo tissue distribution
FVB/N female mice were injected intravenously with either 1 or 10 nmol RU486-BODIPY and anesthetized 4 hours post-injection. Blood was collected by cardiac puncture and the mice perfused with 20 mL PBS. Tissues were flash frozen and stored at -80 °C prior to processing.
Animal studies followed the NIH guidelines for the care and treatment of experimental laboratory rodents. Preparation for analysis: frozen tissues were weighed and diluted 9-fold with PBS containing 0.1 mg/mL DNAase I (Sigma #DN25) then probe-sonicated (Fisher Scientific Sonic Dismembrator 500) on ice until completely homogenized (1-2 cycles, 10 seconds each).
To 100 µL homogenate, or blood, was added 300 µL ACN containing 2.5 % acetic acid. The mixture was vortexed, bath-sonicated for 5 minutes then centrifuged at 14,000 rpm for 5 minutes. The supernatant was used for further analysis. Analysis: samples were subjected to HPLC/MS/MS analysis and tissue concentration was quantified using an RU486-BODIPY standard calibration curve.
Statistical methods
Data were expressed as mean ± s.d. for all experiments. Statistical significance was determined using an unpaired two-tailed t-test compared to control except for in vivo tissue distribution analysis where a paired one-tailed t-test was applied (under the assumption that target organs are expressing higher levels of progesterone receptor.) 
